At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
Marina Kremyanskaya, MD, PhD
Advertisement
Marina Kremyanskaya, MD, PhD, is an associate professor of medicine at the Icahn School of Medicine at Mount Sinai.
Articles by Marina Kremyanskaya, MD, PhD
Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels and improving iron regulation, according to lead investigator Marina Kremyanskaya, MD, PhD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
2
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
3
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
4
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
5